We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HAGA:OMXICEHagar hf. Analysis

Data as of 2026-05-25 - not real-time

ILA 1,620.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at 1,620, comfortably above its 20‑day SMA (1,584) and well above the 50‑day (1,453.88) and 200‑day (1,125.50) averages, suggesting a short‑term bullish bias. However, the MACD histogram is negative (-3.10) and the MACD signal is labeled bearish, indicating weakening momentum. RSI sits at 59.5, still below overbought levels but edging toward the upper range, reinforcing a cautious outlook. Volatility is elevated at 53% over the past 30 days, while beta is low (0.23), meaning price swings are large but not strongly correlated with the market. Valuation metrics are extreme: a price‑to‑book of 14.1 and price‑to‑sales of 64, far above industry norms, and the company reports negative EPS (-0.51) with zero forward earnings. The balance sheet is strained with a debt‑to‑equity ratio of 158 and negative operating and free cash flow, while cash holdings (≈26 M) are dwarfed by debt (≈155 M). No dividend is paid, making dividend sustainability a non‑issue. Volume trends are decreasing, raising liquidity concerns. Taken together, the technical upside is outweighed by fundamental weakness and lofty valuations, suggesting a defensive stance.
Investors should monitor the price as it approaches the key resistance near 1,777 and the support at 1,391, but the current risk‑reward profile leans toward caution. The extreme greed sentiment in the market (Fear & Greed Index 91.6) may be inflating price expectations beyond what the fundamentals can justify.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish MACD histogram indicating weakening momentum
  • Extremely high valuation multiples (P/B 14.1, P/S 64)
  • Negative cash flows and high debt burden

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Price remains above major moving averages supporting a residual bullish bias
  • Volatility remains elevated, increasing uncertainty
  • Fundamental deficits persist with no earnings recovery in sight

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Unsustainable capital structure (debt‑to‑equity >150)
  • Zero dividend and negative EPS limiting long‑term returns
  • Overvaluation likely to correct as market sentiment normalizes

Key Metrics & Analysis

Financial Health

Revenue Growth971.40%
Profit Margin52.19%
ROE10.33%
ROA3.80%
Debt/Equity158.34
P/B Ratio14.1
Op. Cash FlowILA-13719000
Free Cash FlowILA-21506000
Industry P/E32.7

Technical Analysis

TrendBullish
RSI59.5
SupportILA 1,391.00
ResistanceILA 1,777.00
MA 20ILA 1,584.00
MA 50ILA 1,453.88
MA 200ILA 1,125.50
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta0.23
Volatility53.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.